Suppr超能文献

双相 I 型障碍中的抗抑郁药治疗与躁狂发作转换:一项临床与分子遗传学研究

Antidepressant Treatment and Manic Switch in Bipolar I Disorder: A Clinical and Molecular Genetic Study.

作者信息

Chen Chih-Ken, Wu Lawrence Shih-Hsin, Huang Ming-Chyi, Kuo Chian-Jue, Cheng Andrew Tai-Ann

机构信息

Community Medicine Research Center & Department of Psychiatry, Chang Gung Memorial Hospital, Keelung 204, Taiwan.

College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.

出版信息

J Pers Med. 2022 Apr 11;12(4):615. doi: 10.3390/jpm12040615.

Abstract

Affective switch is an important clinical issue when treating bipolar disorder. Though commonly seen in clinical practice, the benefits of prescribing antidepressants for bipolar depression are still controversial. To date, there have been few genetic studies and no genome-wide association study (GWAS), focusing on manic switch following bipolar depression. This study aims to investigate the effects of individual genomics and antidepressant medication on the risk of manic switch in bipolar I disorder (BPI). A total of 1004 patients with BPI who had at least one depressive episode with complete data on antidepressant treatment and outcome were included. Clinical assessment of mania and depression was performed by trained psychiatric nurses and psychiatrists using the Chinese version of the Schedules for Clinical Assessment in Neuropsychiatry (SCAN), and the diagnosis of BPI was made according to DSM-IV criteria. Manic switch was defined as a manic episode occurring within eight weeks of remission from an acute depressive episode. The age at first depressive episode of the study patients was 30.7 years (SD 12.5) and 56% of all patients were female. GWAS was carried out in a discovery group of 746 patients, followed by replication in an independent group of 255 patients. The top SNP rs10262219 on chromosome 7 showed the strongest allelic association with manic switch (p = 2.21 × 10−7) in GWAS, which was however not significantly replicated. Antidepressant treatment significantly (odds ratio 1.7; 95% CI 1.3−2.2; p < 0.001) increased the risk of manic switch. In logistic regression analysis, the CC genotype of rs10262219 (odds ratio 3.0; 95% CI 1.7−5.2) and antidepressant treatment (odds ratio 2.3; 95% CI 1.4−3.7) significantly increased the risk of manic switch with a joint effect (odds ratio 5.9; 95% CI 3.7−9.4). In conclusion, antidepressant medication and rs10262219 variants jointly increased the risk of manic switch after bipolar depression.

摘要

情感转换是双相情感障碍治疗中的一个重要临床问题。尽管在临床实践中很常见,但为双相抑郁患者开具抗抑郁药的益处仍存在争议。迄今为止,很少有基因研究,也没有全基因组关联研究(GWAS)关注双相抑郁后的躁狂转换。本研究旨在调查个体基因组学和抗抑郁药物对I型双相情感障碍(BPI)躁狂转换风险的影响。共纳入1004例BPI患者,这些患者至少有一次抑郁发作,且有关于抗抑郁治疗及结果的完整数据。由经过培训的精神科护士和精神科医生使用中文版神经精神疾病临床评定表(SCAN)对躁狂和抑郁进行临床评估,并根据DSM-IV标准诊断BPI。躁狂转换定义为在急性抑郁发作缓解后八周内出现躁狂发作。研究患者首次抑郁发作的年龄为30.7岁(标准差12.5),所有患者中56%为女性。在一个由746例患者组成的发现组中进行了GWAS,随后在一个由255例患者组成的独立组中进行了重复验证。7号染色体上的顶级单核苷酸多态性(SNP)rs10262219在GWAS中显示出与躁狂转换最强的等位基因关联(p = 2.21×10−7),然而并未得到显著重复验证。抗抑郁治疗显著增加了躁狂转换的风险(比值比1.7;95%置信区间1.3 - 2.2;p < 0.001)。在逻辑回归分析中,rs10262219的CC基因型(比值比3.0;95%置信区间1.7 - 5.2)和抗抑郁治疗(比值比2.3;95%置信区间1.4 - 3.7)显著增加了躁狂转换的风险,且存在联合效应(比值比5.9;95%置信区间3.7 - 9.4)。总之,抗抑郁药物和rs10262219变异共同增加了双相抑郁后躁狂转换的风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7727/9033004/41e6e0441488/jpm-12-00615-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验